Scientists analyzed almost 200 cannabis genomes to create the most comprehensive, high-quality, detailed genetic atlas of the plant to date. The atlas reveals unprecedented diversity and complexity ...

Traditional, Complementary, and Integrative Medicine (TCIM) is a significant resource for long-term health, recognized by the ...

The next-gen immunotherapies market is evolving with biotech advances, rising cancer cases, new therapies, funding, and ...

The day-long event also featured talks that touched upon several other advances in the biotech space like engineering RNA biology with AI, building prostheses along with a prototyping workshop.

The global sales of peptide therapeutics is estimated to be worth USD 42.1 billion in 2024 and anticipated to reach a value ...

dAgeing Research at King's and School of Cardiovascular Medicine and Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK ...

offers a sweeping and authoritative synthesis on the use of liquid biopsy in gynecological oncology placing this emerging tool at the forefront of precision medicine for women. Led by Professor ...

PDS Biotechnology Corp (NASDAQ ... A: Dr. Kirk Shepard, Chief Medical Officer, explained that the KEYNOTE-689 trial primarily involved HPV negative patients, with only 3% to 4% being HPV positive.

Moleculin Biotech Inc (NASDAQ:MBRX) has officially started the Phase 3 Miracle trial for Anamycin, with the first patient already treated and 38 sites selected worldwide. The European Medicines ...

Analyst questions reflected continued scrutiny of enrollment pace and resource allocation. PDS Biotech’s first quarter of 2025 was marked by the advancement of the VERSATILE-003 Phase 3 trial ...

Shortly afterward, up-and-coming venture capitalist Robert Swanson pitched Boyer on co-founding the first biotech company, which they named Genentech, Inc. Boyer and Cohen had produced a new era of ...